Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd	
ABN	38 620 388 230	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Ryan Laws
Date of last notice	13 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Skaha Investments Pty Ltd – Director and Shareholder
Date of change	19 December 2018
No. of securities held prior to change	Mr Ryan Michael Laws 60,381 ordinary shares (EMV) 3,152,119* ordinary shares (EMV) 3,212,500 total ordinary shares (EMV) 500,000* unlisted options, exercise price 35c, expiry date 31 Dec 2021 * restricted until 13 Dec 2021
Class	Ordinary shares
Number acquired	70,000

⁺ See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$21,180.00
No. of securities held after change	Mr Ryan Michael Laws 60,381 ordinary shares (EMV) 3.152,119* ordinary shares (EMV) 3.212,500 total ordinary shares (EMV) 500,000* unlisted options, exercise price 35c, expiry date 31 Dec 2021 * restricted until 13 Dec 2021 Skaha Investments Pty Ltd 70,000 ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market purchases

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	

⁺ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd	
ABN	38 620 388 230	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Scott Kirkland
Date of last notice	13 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

I	
(including registered holder) Note: Provide details of the circumstances giving rise to the relevant	KIRKLAND CAPITAL PTY LTD <thrill a="" c="" furkhand=""> - Controller of Trustee and beneficiary of trust</thrill>
_	1. 20 December 2018 2. 21 December 2018
3 3 1 1 2 4	Mr Scott Philip Kirkland 112,387 ordinary shares (EMV) 3,167,613* ordinary shares (EMV) 3,280,000 total ordinary shares (EMV) 600,000* unlisted options, exercise price 35c, expiry date 31 Dec 2021 KIRKLAND CAPITAL PTY LTD <thrill a="" c="" furkhand=""> 160,800 ordinary shares (EMV) 254,200* ordinary shares (EMV) 415,000 total ordinary shares (EMV) * restricted until 13 Dec 2021</thrill>

⁺ See chapter 19 for defined terms.

Class	Ordinary shares
Number acquired	1. 35,634 2. 17,766 Total – 53,400
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$10,796.55 2. \$5,400.63 Total - \$16,197.18
No. of securities held after change	Mr Scott Philip Kirkland 165,787 ordinary shares (EMV) 3.167,613* ordinary shares (EMV) 3.333,400 total ordinary shares (EMV) 600,000* unlisted options, exercise price 35c, expiry date 31 Dec 2021 KIRKLAND CAPITAL PTY LTD <thrill a="" c="" furkhand=""> 160,800 ordinary shares (EMV) 254,200* ordinary shares (EMV) 415,000 total ordinary shares (EMV) * restricted until 13 Dec 2021</thrill>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market purchases

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written	No
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Geoff Pocock
Date of last notice	13 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	OOFY PROSSER PTY LTD <drones a="" c="" family=""> - Trustee and beneficiary of trust</drones>
Date of change	1. 18 December 2018 2. 19 December 2018
No. of securities held prior to change	OOFY PROSSER PTY LTD <drones a="" c="" family=""> 72,000 ordinary shares (EMV) 193,000* ordinary shares (EMV) 265,000 total ordinary shares (EMV) 500,000* unlisted options, exercise price 35c, expiry date 31 Dec 2021 * restricted until 13 Dec 2020</drones>
Class	Ordinary shares

⁺ See chapter 19 for defined terms.

Number acquired	1. 35,000 2. 50,000 Total – 85,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$10,629.92 2. \$15,040.63 Total - \$25,670.55
No. of securities held after change	OOFY PROSSER PTY LTD <drones a="" c="" family=""> 157,000 ordinary shares (EMV) 193,000* ordinary shares (EMV) 350,000 total ordinary shares (EMV) 500,000* unlisted options, exercise price 35c, expiry date 31 Dec 2021 * restricted until 13 Dec 2020</drones>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market purchases

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	

⁺ See chapter 19 for defined terms.